Clinical Significance of Molecular Biomarkers on Brain Gliomas

Gliomas are the most common primary brain tumors, and more than half of them are glioblastoma multiformes (GBMs) with the highest heterogeneity malignant degree. According to the statistical report of the Central Brain Tumor Registry of the United States, the glioma patients in the United States accounted for 26% of all intracranial tumor patients and 81% of all intracranial malignant tumor patients in 2011-2015 [1]. The overall survival (OS) of patients with gliomas has always beensatisfactory. Although the patients with GBMs underwent standardized treatment, the median OS of them is only about 12 months [2]. Therefore, it is very important to further clarify the pathogenesis of glioma, find new targets and put forward new diagnostic and prognostic biomarkers. Some patients with the same pathological diagnosis have great differences in the OS, which indicates the deficiency of traditional pathological indicators in judging the prognosis of patients. In recent years, great progress has been made in the study of molecular biomarkers which are helpful to the clinical diagnosis and prognosis of gliomas have been found. To further understand the molecular biological characteristics of glioma and identify more potential molecular markers is of great significance for revealing the pathological mechanism and clinical diagnosis and prognosis of glioma.